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of death from any cause or hospitalization for heart 
failure) did not differ significantly between the two 
groups; there were 53 events in the dronedarone group 
(17.1%) and 40 events in the placebo group (12.6%) (HR, 
1.38; P = 0.12). More increases in the creatinine 
concentration were reported as serious adverse events in 
the dronedarone group than in the placebo group. The 
authors concluded that in patients with severe heart 
failure and left ventricular systolic dysfunction, treatment 
with dronedarone was associated with increased early 
mortality related to the worsening of heart failure. 
The results of the above two studies diverge from 
those of earlier studies, like the ATHENA trial,4 but this 
does not offer any re-assurance on the use of dronedarone 
in patients with any risk factors. Dronedarone’s use has 
thus been restricted to maintenance of sinus rhythm in 
patients with paroxysmal AF and no underlying heart 
disease. It is contraindicated in patients with permanent 
AF and patients with current or previous episodes of heart 
failure or left ventricular systolic dysfunction, as 
detrimental effects of dronedarone have been documented 
in these groups of patients. In the ATHENA trial, patients 
with persistent AF also received the drug without 
apparent harm, but the definition of persistent and 
permanent AF is not that clear, and thus, great caution 
should be exercised in the persistent AF group, as well. 
Whether there will be a return of dronedarone for a 
second chance after this recent potentially fatal blow or 
setback remains doubtful. All these drawbacks taken 
together with the harmful effects of the drug on the liver 
with reported cases of liver damage necessitating liver 
transplantation make everybody heavily pensive and 
hesitant in ever using this pharmaceutical agent.5,6
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In our aging society, most of the elderly aged >65 years are 
affected by systolic hypertension (HTN) [blood pressure (BP) 
>140 mmHg], which constitutes a major risk factor for organ 
damage and cardiovascular (CV) events. Management of HTN 
in the elderly represents a therapeutic dilemma because HTN 
trials had upper age limits or did not present age-specific 
results. However, the HYVET trial documented that therapy is 
beneficial even in those >80 years. In the elderly, systolic BP 
and pulse pressure emerge as potent risk factors for CV events. 
In the past an empiric formula "100+age" was used to estimate
appropriate systolic BP. Diastolic BP is more important in 
younger people <50 years.1
Hypertension in the elderly is due to increased stiffness and 
pulse wave velocity of the great arteries with earlier return of 
reflected waves, causing high systolic BP, low diastolic BP, 
increased myocardial oxygen demand with higher peripheral 
resistance and limited organ perfusion.2 Furthermore, decreased 
renal function contributes to HTN through volume expansion, 
increased intracellular sodium, reduced Na-Ca exchange; K+ 
excretion is limited and plasma aldosterone is low, so that the 
elderly are prone to drug-induced hyperkalemia. Autonomic 
dysfunction and venous insufficiency contribute to orthostatic 
hypotension, resulting in falls, syncope, CV events or 
orthostatic hypotension. Secondary HTN should also be 
considered, including renal artery stenosis, obstructive sleep 
apnea, primary aldosteronism, hyper- or hypo-thyroidism, 
tobacco, alcoholism, caffeine, use of no-steroidal anti-
inflammatory drugs, glucocorticoids, sex hormones.3
Hypertension or poor BP control may affect different 
organs, leading to left ventricular hypertrophy, heart failure, 
arrhythmias, sudden death, coronary atherosclerosis, aortic 
aneurysm and/or dissection, peripheral vascular disease, 
ischemic stroke, cerebral hemorrhage, vascular dementia4 and 
chronic kidney disease (CKD).5 The diagnosis should be based 
on at least 3 different BP measurements, on >2 separate office 
visits, with the patient comfortable seated for at least 5 min. 
Measurements should be obtained in each arm and the arm with 
the highest BP should be used for future BP monitoring. A cuff 
with a bladder that encircles more than 80% of the upper arm 
circumference should be used. Elderly patients should also be 
evaluated for post-prandial and orthostatic hypotension.1
Pseudo HTN, i.e. falsely increased BP from sclerotic arteries 
that do not collapse during inflation of the BP cuff, should be 
suspected in elderly patients with refractory HTN, no organ 
damage and/or symptoms of overmedication. Confirmation 
requires the Osler maneuver or direct intra-arterial BP 
measurement.6,7 White-coat HTN is a persistently elevated 
office BP >140/90 mmHg, together with a normal daytime 
ambula-tory BP (<135/85 mmHg). Ambulatory BP monitoring 
is recommended in persistent office HTN but no organ damage, 
when HTN diagnosis or response to therapy is unclear from
office visits, when syncope or hypotensive disorders are 
suspected and for evaluation of dizziness. Ambulatory systolic 
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BP independently predicts CV mortality.8 Home BP readings
evaluate excessive BP reductions. Electronic automatic devices 
are more convenient and easier to use, however they cannot 
measure BP in patients with arrhythmias, e.g. atrial fibrillation 
with rapid ventricular rate. 
Evaluation of the elderly includes BP measurement, taking 
a good history that includes HTN duration, severity, causes of 
exacerbations, current and previous treatments, other CV risk 
factors or comorbidities; performing a complete physical 
examination, taking patient’s weight and measuring waist 
circumference; performing blood testing that includes sodium, 
potassium, BUN and creatinine with estimated glomerular 
filtration rate, glucose, lipid profile, and glycosylated 
hemoglobin. Patients with HTN, diabetes, and/or CKD should 
be screened for albuminuria. Finally an ECG and an 
echocardiographic examination are deemed indispensable.1
TREATMENT
BP management should aim at maintaining it at <140/90 
mmHg (JNC-7). This target for the elderly is based on expert 
opinion rather than on data from clinical trials. The decision to 
initiate anti-HTN therapy in the elderly should include 
consideration on potential impact on quality of life, because 
comorbid conditions and polypharmacy influence compliance 
and have economical impact for patients and families.
Non pharmacological treatment includes lifestyle 
modifications such as smoking cessation, weight and mental 
stress reduction, dietary Na restriction, Ca2+ - Mg-2 supple-
ments, alcohol reduction (<2 drinks/day), and aerobic exercise, 
which may be the only treatment necessary for milder HTN 
forms. Risk stratification scores are useful; a team approach is 
necessary; telemedicine and text messaging are useful. 
Drug therapy should be started at the lowest dose and 
gradually increased, depending on BP response. Target systolic 
BP is <140 mmHg if tolerated except for octogenarians or 
special populations. If the BP response is inadequate, a second 
drug from another class should be added. When BP remains 
>20/10 mmHg above the goal, therapy should be initiated with
2 anti- HTN drugs. The European Working Party on High BP
in the Elderly (EWPHE) (1980) demonstrated that in patients 
>60 years with BP>160/90 mmHg, drug treatment reduced CV
events. Other studies extended the beneficial effects to patients 
>70 years and to elderly with isolated systolic HTN (systolic 
BP>160 mmHg / diastolic BP<90-95 mmHg).9,10 The HYVET
trial modified previous recommendations for patients >80 years 
and systolic BP>160 mmHg. After 2 years, the trial was 
stopped prematurely because treatment decreased BP (144/78 
mmHg vs 161/84 mmHg) and reduced adverse outcomes.11
Despite several limitations of the trial, the extension phase of 
the HYVET reinforced the conclusion that treatment of HTN in 
octogenarians is beneficial, although BP control is difficult to 
achieve, given the low adherence to therapy.12 Other reasons 
for inadequate BP response include volume overload, drug
interactions, pseudo resistance, secondary hypertension, age-
related physiological changes in drug absorption and 
distribution, declines in renal and/or hepatic function, 
contracted intravascular volumes and impaired baroreflexes. 
Furthermore, many physicians are less aggressive to treat the 
elderly believing that treating hypertensive octogenarians 
entails more risks than benefits.   
Diuretics. The majority of hypertensive patients are 
controlled on diuretic monotherapy. Thiazide diuretics are most 
commonly used in clinical practice (chlorothiazide,
chrorthalidone, indapamide and metolazone). They are secreted 
into the proximal convoluted tubule and act in the distal tubule 
by inhibiting the Na-Cl symport in the luminal membrane and 
also the water and electrolyte reabsorption. In severe CKD
(creatinine clearance <30 ml/m), heart failure, and liver 
cirrhosis, thiazide diuretics are not effective. Side effects 
include dysglycemias, dyslipidemia, hypercalcemia, hyper-
uricemia, pancreatitis, photosensitivity and hypersensitivity to 
sulfonamides. Nevertheless, diuretics may reduce CV events in 
the elderly to a similar extent as other drug classes. 
Loop diuretics (furosemide, bumetanide and torsemide) are 
used in HTN associated with heart failure and/or CKD. They 
may increase blood sugar and cause headache, fever, anemia, 
and/or electrolyte disturbances. Potassium sparing diuretics 
(amiloride, triamterene, spinonolactone, eplerenone) are 
important in patient protection from hypokalemia and also 
treating secondary hyperaldosteronism.13
Beta-blockers are useful in combination therapy in 
arrhythmias, migraine headaches, senile tremor, coronary artery 
disease, and heart failure. Side effects include depression, 
sexual dysfunction, dyslipidemia, dysglycemia,14,15 but newer 
agents, such as nebivolol, are better tolerated and have 
favorable outcomes (SENIORS trial).16
Alpha-blockers are not first line therapy in the elderly, 
although they are used for prostate hypertrophy. They are 
efficient but doxazocin showed an increase in CV events driven 
by an increase in heart failure and stroke (ALLHAT). Side 
effects include orthostatic hypotension and first dose syncope.17
Alpha-Beta-blockers are used in HTN urgencies or 
emergencies (labetalol), or in congestive heart failure 
(carvedilol).18 However, their use in the elderly is not 
recommended due to the possibility of orthostatic HTN.
Calcium antagonists comprise phenylalkylamines 
(verapamil), benzothiazepines (diltiazem), or dihydropyridines 
(nifedipine, nicardipine, nimodipine, amlodipine, felodipine, 
isradipine, nitrendipine). They are appropriate for elderly 
patients with HTN and increased arterial stiffness, diastolic 
dysfunction, angina, or supraventricular arrhythmias. Adverse 
events include vasodilatation (ankle edema, headache, 
hypotension, dizziness, falls), and deterioration of underlying 
conduction defects. Diltiazem and verapamil may be useful in 
left ventricular diastolic dysfunction but may increase 
constipation and precipitate heart block. They should be 
avoided in systolic heart failure due to negative inotropy.
Angiotensin converting enzyme (ACE) inhibitors block 
conversion of angiotensin (AT)-I to AT-II in tissues and 
plasma, lowering peripheral vascular resistance and BP without 
reflex stimulation of heart rate.19 They are the drugs of choice 
in patients with heart failure whereby they reduce morbidity 
and mortality, in diabetes and/or CKD where thay reduce 
progression of diabetic CKD and hypertensive 
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nephrosclerosis.20 Furthermore, they reduce stroke-related 
dementia and/or stroke (PROGRESS trial). Adverse effects
comprise hypotension, dry cough, rarely angioedema or rash; 
hyperkalemia in CKD or in those taking K+ supplements or K+
sparing diuretics; rarely neutropenia, agranulocytosis and renal 
failure in patients with renal artery srenosis.
Angiotensin receptor blockers (ARBs) are similar to other 
agents in BP reduction and well tolerated.21 They protect the 
kidney in diabetes22 and reduce mortality and morbidity in 
heart failure.23 They are first line therapy in HTN and diabetes 
and second-line therapy in patients with HTN and heart failure 
who cannot tolerate ACE inhibitors.24,25
Renin inhibitor, aliskiren, is effective for BP management. 
Combined with thiazide or amlodipine may be more effective 
than ramipril.26 However, evidence is lacking on combination
of aliskiren with other agents;27 rather, the premature 
discontinuation of the ALTITUDE study (19/12/2011), which 
showed no benefit from aliskiren added to an ACE inhibitor or 
ARB, while patients treated with it had more CV and renal 
problems, led to issuance of a warning advisory against its use.
Direct vasodilators (hydralazine, minoxidil) are potent 
vasodilators as fourth-line therapy. Hydralazine causes 
tachycardia, fluid accumulation, atrial arrhythmias. Nitrates 
have no role in chonic HTN because of tolerance. 
Centrally acting agents (e.g. clonidine) are effective in 
reducing catecholamines but patients develop sedation and 
bradycardia, while abrupt discontinuation leads to a rebound 
phenomenon with excessive BP increase.
Combination therapy is more efficient, avoids adverse 
effects as drugs are administrated at lower doses, is convenient, 
leads to drug synergism and enhanced patient compliance and 
exploits drug pleiotropic effects. 
RESISTANT HTN
Resistant or drug-refractory hypertension is defined as HTN 
not controlled with combination therapy that includes at least 3 
different categories of medications, one of which is a diuretic. 
In these cases one should pay attention to uncover patient 
compliance, excessive salt intake or underlying causes of 
secondary hypertension. Recently, novel modalities have been 
introduced, with the most promising approach that of renal 
artery denervation, affected via radiofrequency ablation. 
FUTURE CONSIDERATIONS
Prevention of HTN is always preferable to treatment and 
could be effected via lifestyle changes and with early blockade 
of the renin angiotensin aldosterone system in HTN-stage 1 in 
order to effectively limit hypertensive disease. Future research 
should be directed at the pathogenesis of increased vascular and 
left ventricular stiffness; defining appropriate thresholds and 
goals of therapy and comparing drug efficacy; and devising 
potential new therapeutic strategies. 
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